The innate immune system mediates very effective recognition of invading bacteria on a molecular level by receptor/sensor proteins localized at the cell surface and intracellular sites. Due to this high affinity binding of response triggering bacterial molecules at picomolar concentrations, practical laboratory work is driven to the cutting edge of what can be achieved technically concerning isolation, analysis, purification or contaminants detection. Hence, when interpreting bioactivities of LPS, lipid A and LPS/lipid A substructures it matters if they are obtained from natural sources or chemical synthesis [5]. As revealed in the last two decades, two accessory extracellular proteins, LPS-binding protein (LBP) and CD14 significantly contribute to the extreme sensitivity of mammlian innate immunity to LPS by specific extraction of a single LPS moiety from endotoxin aggregates or bacterial membranes and its transfer to the TLR4/MD-2 heterodimer [6,7].
yields lipid A still capable of inducing endotoxicity (15 in [3] ), even if exceptions have been reported [4] .
The innate immune system mediates very effective recognition of invading bacteria on a molecular level by receptor/sensor proteins localized at the cell surface and intracellular sites. Due to this high affinity binding of response triggering bacterial molecules at picomolar concentrations, practical laboratory work is driven to the cutting edge of what can be achieved technically concerning isolation, analysis, purification or contaminants detection. Hence, when interpreting bioactivities of LPS, lipid A and LPS/lipid A substructures it matters if they are obtained from natural sources or chemical synthesis [5] . As revealed in the last two decades, two accessory extracellular proteins, LPS-binding protein (LBP) and CD14 significantly contribute to the extreme sensitivity of mammlian innate immunity to LPS by specific extraction of a single LPS moiety from endotoxin aggregates or bacterial membranes and its transfer to the TLR4/MD-2 heterodimer [6, 7] .
In LPS of wild-type enterobacteria an inner and outer core region and the strain-specific O-specific chain have been defined in the polysaccharide region based on evolutionary variation. In a set of specific enterobacterial glycosyltransferase mutants diplaying a rough (R)-type colony form only partial poly/oligo saccharide structures are expressed.
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Abstract: There is literature evidence gathered throughout the last two decades reflecting unexpected species differences concerning the immune response to lipid IVa which provides the opportunity to gain more detailed insight by the molecular modeling approach described in this study. Lipid IVa is a tetra-acylated precursor of lipid A in the biosynthesis of lipopolysaccharide (LPS) in Gram-negative bacteria. Lipid A of the prototypic E. coli-type is a hexa-acylated structure that acts as an agonist in all tested mammalian species by innate immunorecognition via the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 2 (MD-2) receptor complex. In contrast, lipid IVa is proinflammatory in mouse cells (agonism) but it remains inactive to human macrophages and even antagonizes the action of potent agonists like E. coli-type lipid A. This particular ambivalent activity profile of lipid IVa has been confirmed in other mammalian species: in equine cells Lipid IVa also acts in a weak agonistic manner, whereas being inactive and antagonizing the lipid A-induced activation of canine TLR4/MD-2. Intriguingly, the respective TLR4 amino acid sequences of the latter species are more identical to the human (67%, 68%) than to the murine (62%, 58%) ortholog. In order to address the unpaired activity-sequence dualism for human, murine, canine and equine species regarding the activity of lipid IVa as compared to LPS and lipid A and, we review the literature and computationally pinpoint the differential biological effects of lipid IVa versus LPS and lipid A to specific amino acid residues. In contrast to lipid IVa the structurally related synthetic compound Eritoran (E5564) acts consistently in an antagonistic manner in these mammalian species and serves as a reference ligand for molecular modeling in this study. The combined evaluation of data sets provided by prior studies and in silico homology mapping of differential residues of TLR4/MD-2 complexes lends detailed insight into the driving forces of the characteristic binding modes of the lipid A domain in LPS and the precursor structure lipid IVa to the receptor complex in individual mammalian species. (Figure 1, panel B) . More in detail, within this hexa-acylated structure a subset of four 3-hydroxymyristoyl (3-OH-C14) residues is attached directly to the β-D-glucosaminyl-(1,6)-β-Dglucosamine backbone by two amide and two ester bonds at positions 2/2´and 3/3´, respectively, and the 3-OH-groups of both of the ´primary´ residues at positions 2´and 3´on GlcN II are further esterified to a lauroyl (C12) and a myristoyl (C14) group, respectively. The two phosphate residues of the lipid A's backbone differ -glycosidic linkage to the reducing monomer (GlcN I) in position C1 of the disaccharide scaffold and the other is ester-bound to position 4' of the nonreducing pyranose unit (GlcN II) [9] . The (-) sign marks the 2 and 6 negative charges in lipid A and the inner core, respectively. Additionally given (Figure 1 
Reviewing and identifying

TLR4 / MD-2 receptor complexes
As compared to the ubiquitous activation of mammalian TLR4/MD-2 signaling by enterobacterial LPS or lipid A, particular lipid A substructures like the tetra-acylated biosynthetic precursor Lipid IVa or its synthetic analogue compound 406 act either as antagonists or weak receptor agonists in a species-dependent manner ( Figure 1 , panel C). In contrast, the tetra-acyl compound Eritoran (E5564) acts as a TLR4/MD-2 receptor antagonist in all mammalian species investigated to date ( Figure 1, panel D) .
The lipid A-specific interaction between the complex of the solenoid TLR4 ectodomain and MD-2 with LPS induces a rearrangement and dimerization to an "m-shaped" signaling complex of two TLR4/MD-2/LPS units [8] (Figure 2 ). This LPS/lipid Ainduced formation of the dimeric (TLR4/MD-2/LPS)2 complex on the cellular surface constitutes a key step to activate the innate immune system in mammalian species [9, 10] . In addition, X-ray crystal structures of human MD-2 either alone or in an 1:1 association with a partial structure of the human TLR4 ectodomain have shown that the tetra-acylated ligands lipid IVa and Eritoran also bind to the central binding cleft of human MD-2, but in a largely different and thus non-agonistic orientation as compared to the lipid A domain of LPS [11, 12] . Furthermore, x-ray structural data of the radioprotective 105 kDa (RP105) ectodomain/ myeloid differentiation factor 1 (MD-1) complex representing a major negative feed-back-regulatory element of LPS-induced TLR4/MD-2-signaling have revealed a ligand-independent dimer formation of two RP105/MD-1 units in an inverse orientation as compared to the (TLR4/MD-2-LPS)2 complex [13, 14] .
In general, loss of one or both phosphate groups, underacylation and/or the replacement of single or multiple acyl residues within the characteristic pattern of five n-(hydroxy)myristoyl chains plus one nlauroyl residue by shorter acyl chains lead to partial or total loss of immunoactivity [5, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . The binding to TLR4/MD-2 is TLR4 / MD-2 receptor complexes completely lost when both of the two phosphate groups are removed indicating their importance for providing binding affinity in all partial structures of enterobacterial lipid A tested [16, 24, 31] . The activity is, however, preserved when a carboxyl group replaces the phosphate group on LPS [32]. This indicates a major contribution of negative charges in lipid A-binding to TLR4/MD-2 mediated by positively charged amino acids on TLR4 and MD-2. Another example of a lipid A derivative/partial structure with reduced overall negative charge is 4´-monophosphoryl lipid A (MPLA), which has been shown to display markedly reduced TLR4/MD-2 agonistic activity as compared to the diphosphorylated lipid A parent structure. Binding of these ligands to the receptor binding site leads to only partial activation of the TLR4/MD-2-connected intracellular signaling network of as compared to the full agonist (lipid A), thus resulting in incomplete signaling [28] . In comparison to lipid A, 4´-monophosphoryl lipid A (MPLA) lacks one phosphate group and is therefore unable to contact some positively charged residues on the surface of both MD-2 and TLR4 [2, 8] . Recently, it was observed that the presence or absence of the oligosaccharide core segment from Capnocytophaga canimorsus LPS modulates endotoxic potency (Table 1 ). The structural implications were also discussed based on molecular dynamics simulations of the liganded human MD-2 monomer with lipid A from C. canimorsus and E. coli [4] .
Site-directed mutagenesis data of liganded TLR4/MD-2 complexes
Various lipid A derivatives or analogous agents (Figure 1 ) with a common amphipathic glycolipid scaffold have been described to represent LPS/lipid A-like activators (agonists) or TLR4/MD-2 signaling or inhibitors (antagonists) of LPS-induced cellular immunoactivities [2, 25, 28, 49, 50] . LPS receptor inhibitors are being developed as potential drugs for adjunct treatment of septic shock patients with Gram-negative septic infection (endotoxicity). Lipid IVa, a tetra-acylated lipopolysaccharide precursor in the biosynthesis of Escherichia coli or Salmonella lipid A, is an agonist in murine myeloid cells but it remains inactive to human macrophages and even antagonizes the action of potent agonists like E. coli-type hexaacylated LA. In contrast to lipid IVa, however, the synthetic compound Eritoran that also comprises of only four acyl chains is a potent TLR4/MD-2 receptor antagonist in human, murine and equine species and can be considered as an investigational drug against bacterial sepsis [2], (48,51,75 in [46] ).
Site directed mutagenesis approaches have revealed involvement of species-specific residues in MD-2 [36] and TLR4 in agonistic/antagonistic activities of lipid IVa (Table 2) [8, 37, 51, 52] . Hence these mutagenesis data indicate, that both MD-2 and TLR4 contribute to the species-specific response to lipid IVa [12, 15, 36, 37, 53, 54] . For example Thr57, Val61, and Glu122 of mouse MD-2 may have an impact on activation of the murine receptor complex by lipid IVa [36] . TLR4 was also subject to a set of selective human/horse sequence conversion mutants like R385G [51, 52] .
Dimerization and activities in crystal structures
With the 2012 release of the crystal structures of the mouse TLR4/MD-2/L4a and TLR4/MD-2/Re-LPS complexes (PDB codes: 3VQ1, 3VQ2) [15] it became possible to compare two complementary functional pairs (Table 3) The oligomerization state is different for the liganded and unliganded complexes and it also depend on the environment: In 2007 it was described that LPS binding induces the dimerization of hTLR4/MD-2 [55]. Crystallography (Table 3) showed unambiguously the dimeric structures of human (TLR4/MD-2/LPS)2 [48] and mouse (TLR4/MD-2/LPS)2 complexes [15] . In native gel electrophoresis experiments the complex was shown to be a dimer: m(TLR4/MD-2/Re-LPS)2. In contrast, when bound to lipid IVa the complex remained monomeric m(TLR4/MD-2/L4a) in solution according to the electrophoretic mobility shift data. However, the lipid IVa murine complex was dimeric in the crystal form: (TLR4/MD-2/L4a)2 [15] . The authors ascribe its missing dimerization in solution to weaker noncovalent forces in the dimerization interface, assuming that the dimerization would be enhanced in the membrane where movements are restricted to the cell surface to facilitate contacts. If this holds, then the structural events as observed by crystallography of mouse (TLR4/MD-2/L4a)2 and human MD-2/L4a monomer are in close keeping with the biological function of either agonism (mouse) or antagonism (in human cells).
As pointed out by Park and colleagues [8] the initial comparison of the human dimeric (TLR4/MD-2/Ra-LPS)2 crystal structure (PDB code: 3FXI) with the monomeric antagonist complexes of lipid IVa with human MD-2 (PDB code: 2E59) and Eritoran with a TLR4/MD-2 fragment (PDB code: 2Z65), revealed that the presence of the two additional (secondary) acyl residues in the lipid A domain of Ra-LPS is correlated with a relative upward shift of the diphosphorylated glucosamine backbone by approximately 5 Å towards the solvent area. This structural shift allows phosphate groups of LPS to contribute to receptor multimerization by forming ionic interactions with a cluster of positively charged residues in human TLR4 and MD-2. The results of the pairwise superimposition of this set of four crystal structures (Table 4) 
Dimerization and signaling
Mechanistically different aspects of signaling are in discussion: ligand-induced oligomerization, cytoplasmically driven selfassociation or agonistic dimerization [15, 20, 56] . LPS binding to the cell surface receptor TLR4 constitutes the extremely specific and effective agonistic stimulus for transmembrane signaling via connecting Toll/IL-1R endodomain (TIR) to mount an immediate immune response. Intriguingly, recent experiments on replacement of the TLR4 ectodomain with MD-2, CD14, monomeric fluorescent protein or a 24 kDa gyrase B fragment revealed a robust ligandindependent constitutive activation of signaling by the corresponding chimeric fusion proteins, comparable to the maximal stimulation of the receptor with LPS. As discussed by the authors this indication for an intrinsic dimerization propensity of the transmembrane and cytoplasmic domains of TLR4 and reveals a previously unknown function of the ectodomain in inhibiting spontaneous receptor dimerization, since the unliganded TRL4 receptor complex must be kept in an inactive state without release of undesired immune responses [57] .
In 2009, Meng et al. published mutational observations about important residues on the TLR4/MD-2 protein complex which were animated through our SPL scripting in the 3D models (Table 5 ) [37] . Surprisingly, the equine residues are identical with human residues contrary to what could be expected from their activity differences concerning lipid IVa. It acts as an antagonist in human cell tests but as a full or partial agonist in mouse or horse systems, respectively.
TLR4 / MD-2 receptor complexes
More in detail, the backbones substructures of agonists were consistently found to display an orientation with the reducing glucosamine-1-phosphate unit facing the secondary (signaling) dimerization site at the open side of the MD-2 pocket, whereas the antagonists were consistently crystallized in the inverted backbone orientation, rotated (´flipped´) by 180° as compared to the agonistic ligands. Moreover, the hydrophilic backbone structures of all agonistic ligands have been found to be placed in a significantly upward shifted position relative to MD-2 surface as compared to the antagonists. Now, it is to say, that contrary to classical pharmacology, where drugs act as either (full or partial) agonists or antagonists, lipid IVa acts either as an antagonist or an agonist in a characteristic speciesdependent manner. Evidently, there is not a corresponding ´classical´ structure-activity relationship for lipid IVa, since the ligand structure is the same. However, a correlation has been revealed between the species-characteristic agonist versus antagonist activities of lipid IVa and the overall binding mode this particular ligand i.e. how deep lipid IVa is buried in the MD-2 pocket and which mode of backbone orientation is present along the binding cleft. Apparently, when this tetra-acylated ligand binds very deeply into the pocket, then the specific unit of one phosphate group (and/or any acyl equivalent nearby, KDO) is not exposed on the dimerization side of the TLR4/MD-2/L4a monomer in order to attract a second monomer. This species-related TLR4/MD-2/L4a monomer thus fails in attracting a second monomer to initiate dimerization and consecutive downstream signaling.
In this view, lipid IVa appears to be rather an imperfect agonist than an agent with dual activity. As a comparably lower affinity ligand, it can bind in species-dependent manner either in an agonistic orientation (with its more surface-exposed backbone as found in the murine receptor complex) or the antagonistic orientation (with the flipped or inversed di-phospho-di-glucosamine backbone as revealed for the monomeric human MD-2 complex).
The earlier reviewed literature attests that lipid IVa is an agonist in mouse but acts as an antagonist in human cells. It can be assumed, that binding of agonists lead to a dimerization of liganded Toll-like receptor 4 and myeloid differentiation factor 2 complexes which then triggers downstream signaling for anti-inflammatory response. Cytoplasmically-driven self-association was, however, also reported.
Based on the x-ray crystal structures of dimeric TLR4/MD-2*agonist complexes the presentation of the three protein chains in the region of the dimerization interface, i.e. TLR4 (chain A), MD-2 (chain B) and TLR4* (chain C, ´counter´ TLR4) as a triangular interaction zone ("wedge") is a most useful concept to analyze species differences and to predict mutational effects (Figure 3) . In this structural selection the wedge-like area consists of three sides: two partial structures of TLR4 proteins contributing to the ´primary´ and ´seondary´dimerization interfaces and one MD-2 forming the connecting bottom line. On a molecular level the species-dependent activity profiles of lipid IVa are reflected by a concert of conserved and variable amino acids in their respective protein sequences in this wegde-shaped zone.
Dimerization and activity
The differential height of the phosphates above the wedge bottom (MD-2) directly reflects the activity changes between the species. Only a highly exposed phosphate group of the backbone is capable of linking two liganded TLR4/MD-2 units [8] . Hence, this site (labeled as "Pag" in Figure 3 ) is considered to play the key role for switching to agonism (Pag) from antagonism (Pan) and back. While the Pag site contacts the GlcN I phosphate group of all observed agonists, the Pan site interacts with the GlcN II phosphate group of all antagonists as the latter show a flipped backbone.
According to the binding models the equine residue pair eGly322A & eGlu344A at the TLR4 interface corresponds to hGlu321A & hGly343A or mLys319A & mLys341A of the human and murine systems, respectively (Figure 3) . The former two pairs are interrelated in a homologous way. The murine pair differs by two cationic residues and stabilizes the phosphate group in its agonistic site. Moreover, this pair together with others (nonconserved hGly384 vs. mAla382 vs. eArg385) nicely explain the crystallographically observed shift in the wedge's leftmost phosphate groups from a MD-2 assisted antagonistic phosphate binding site (interacting hARG90C) toward the agonistic phosphate site.
TLR4 / MD-2 receptor complexes
Park et al. already mentioned the relevant phosphate bridging of liganded TLR4/MD-2 unit (chains A,C) toward a second or counter-TLR4 (chain B) in the wedge, a concert of interacting residues assists the dimerization interface (Figure 3 ). It can be assumed that homodimerization is signaling relevant, since agonistic lipid IVa appears as (TLR4/MD-2/L4a)2 in mouse complexes [14] which parallels agonistic LPS bound to mouse and human crystal complexes [8, 14] . Very close to the wedge lies a histidine-rich surface patch (never referred to) in the dimerization interface of the two TLR4 proteins (chain A and chain B of 3D template 3FXI [8] , which is the counter TLR4, sometimes labeled as TLR4* in the literature). This dimerization interface probably plays a role in transmembrane signal transduction.
Conclusions
During eons only LPS has been relevant for evolutionary adaptation. During time any random mutations were kept in the genes if they were not detrimental to the LPS recognition (silent point mutations) with the present day consequence that all nonidentical residues in MD-2 and TLR4 sequences do not affect picomolar LPS recognition. However, this is not the case of synthetic lipid IVa which is also a biosynthetic interim in bacterial cells. The hitherto silent mutations for LPS in mammalians become relevant for lipid IVa. Mapping makes the interacting net of amino acids recognizable (Figure 3) . The homodimerization process in mice is helped by a nonconserved nonpolar residue (mAla414B) sitting in opposition to what would be the antagonistic phosphate (Pan) on (counter) TLR4*. Thanks to the nonpolar alanine -anionic repulsion, the phosphate group becomes a theoretical "rejection group" and the phosphate group moves into its agonist position further up as an accessible alternative, which actually is the only solution in the wedge. In its linear elongated conformation the mArg434B can interact with the phosphate group in agonist position. This amino acid is not conserved in horse, but compensated through the presence of eArg385A which moves the phosphate group into an "in-between pose" between aforementioned agonistic phosphate in the upper left corner of the wedge and its antagonistic counterpart in its lower left corner.
Taken together the collected data in a more general view, binding of agonists to TLR4/MD-2 leads to formation of a dimeric (TLR4/MD-2/Ligand)2 complex that efficiently activates downstream signaling to activate the vertebrate innate immune response while antagonists act as competitive inhibitors of agonists by binding to the monomeric TLR4/MD-2 unit in a non-dimerizing and thus non-signaling, hence, unproductive manner. Drawn from the hitherto known crystal structures, there is a complex correlation between binding and biological function regarding the exact ligand positioning and in particular the stretched diphophosphorylated diglucosamine backbone spanning the width of the MD-2 unit reaching from one TLR4 to the other (counter) TLR4* in view of the changing agonistic versus antagonistic activities of complexed ligands.
All agonist ligands have been shown to mediate a specific bridging of two TLR4/MD-2 subunits to dimeric complexes (TLR4/MD-2/Lig)2 in the crystal structures whereas the antagonists apparently do not provide the dimerization of TLR4/MD-2 complexes. A crucial finding is the recognition of a murine acidic residue in the otherwise basic vestibule of MD-2. It leads to a repulsion and phosphate shift into agonist position which enables the ligand backbone to bridge both TLR4/MD-2 units. The right corner of the wedge (Figure 3) is highly conserved and holds the GlcN II phosphate group of agonists or, GlcN1 phosphate of antagonists due to their flipped backbones. This is why liganded TLR4/MD-2 forms most likely the functional biological unit. Hence, it must be considered a "monomer" (strangely, a heteromonomer, so to speak). It constitutes the "attachment point" or devise for the association of another liganded TLR4/MD-2 unit to form the signaling dimer. Schematic view of the wedge, a triangular space between the three interacting polypeptide chains, A, B and C corresponding to TLR4, secondary or counter-TLR4 (labeled TLR4*) and MD-2 proteins, respectively. The numbering of the TLR4 residues refers to the horse sequence. Due to deletions of a few TLR4 residues their numbers differ slightly at equivalent positions: up to equine position number 297: e=h=c=m+1; then from equine position 298 to 560: e = m+3 = h+1 = c+1 or h=m+2=e-1=c-1. For instance, comparison of the residues present in (equine) position 322A indicates repulsion effects for the agonistic phosphate group (Pag) of lipid IVa in human (Glu-321A) and canine (Asp-321A) complexes, but strong attraction for murine (Lys-319A) and less for equine (Gly-322A) systems. In mice, the positions 367B and 434B push the phosphate group into Pag. Position 367B destabilizes Pag as phosphate localization in human, equine and canine systems. On the wedge bottom, MD-2 has a cation-reach vestibule to accommodate (Pag-rejected) phosphate groups in Pan except for mice (mGLU122C). Surrounded by conserved residues, Pag/Pan always accommodates the other (second) phosphate group of lipid IVa. The Pan position is occupied by the GlcN II phosphate group of lipid IVa or Eritoran, while the GlcN I phosphate group of LPS / lipid A occupies Pag. In the highly conserved right corner of the wedge is the all species-shared Pag-Pan site holding the complementary phosphate groups of the backbones: either GlcN I phosphate group for lipid IVa and Eritoran, or GlcN II phosphate group for LPS and lipid A.
